The HIV shot that could change medicine is facing its biggest test: Getting to patients

Trials of lenacapavir, a drug developed by Gilead Sciences, show the twice-a-year shot is almost 100% effective at preventing HIV infection. Ihsaan Haffejee / AFP via Getty Images Gilead's lenacapavir shows near 100% efficacy in preventing HIV with twice-yearly shots, reports The Telegraph . Some Latin American countries face barriers to accessing lenacapavir despite running crucial trials. Beyond price, supply is constrained as Gilead works to scale up production of the sought-after shot. For the first time in the four-decade fight against HIV, there is a "miracle" drug that can all but eliminate the risk of infection, but in the Latin American countries where it was tested, most people can't afford it. Trials show that lenacapavir, made by Gilead Sciences, is almost 100% effective in preventing HIV infection . With just two shots a year, those taking it will avoid contracting the virus even when frequently exposed.